Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, Rabies Vaccine, Freeze-dried
Rabies vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sinovac rabies vaccine | EXPERIMENTAL | Participants will be randomly assigned to receive Sinovac rabies vaccine. |
| Sanofi Pasteur Verorab® | ACTIVE_COMPARATOR | Participants will be randomly assigned to receive the marketed rabies vaccine Verorab® |
| Name | Type | Description |
|---|---|---|
| Rabies vaccine | BIOLOGICAL | Receiving five doses of rabies vaccine manufactured by Sinovac using the "Essen" PEP schedule |
| Verorab® | BIOLOGICAL | Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the "Essen" PEP schedule |
Inclusion Criteria: 1. Populations aged ≥1 years old; 2. Participants and/or participants' parents/legal guardians are able to understand and sign the informed consent form (ICF) voluntarily; 3. Participants are able to comply with the study procedures based on the investigator's assessment; 4. In ...
Rabies vaccine is used for rabies prophylaxis in healthy volunteers, specifically evaluated in a simulated post-exposure prophylaxis regimen. It is an investigational vaccine being studied for its immunogenicity and safety in preventing rabies infection.
Rabies vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company listed on the stock exchange under the ticker SVA. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
Rabies vaccine is currently in Phase 3 clinical development. It is an investigational product and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to assess its immunogenicity and safety in a simulated post-exposure prophylaxis setting.
Rabies vaccine is being studied in a Phase 3 clinical trial with the identifier NCT07055893. This trial, titled 'Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen', is not yet recruiting and aims to enroll 390 participants in Pakistan.
Yes, Rabies vaccine is also known as Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, and Rabies Vaccine, Freeze-dried. These names refer to the same investigational vaccine product being developed by Sinovac Biotech.
Rabies vaccine is a monoclonal antibody modality, though its specific molecular target is not detailed. As a vaccine, it is intended to stimulate the immune system to produce protective antibodies against the rabies virus, providing immunity when used in a post-exposure prophylaxis regimen.